In late 2025, Russian medical researchers officially transitioned from pre-clinical success to human clinical trials for a revolutionary, domestically developed mRNA cancer vaccine. This therapeutic vaccine, developed by the Gamaleya National Research Center (the creators of Sputnik V), represents a landmark shift toward personalized precision medicine designed to treat patients already diagnosed with malignancy. The vaccine leverages advanced messenger RNA (mRNA) technology to instruct the pati

Researchers are developing mRNA-based cancer vaccines designed to train the immune system to recognize and attack cancer cells more effectively. • These vaccines use mRNA technology to target tumor-specific antigens. • They are often personalized, created using genetic information from a patient’s tumor. • Early clinical trials show strong and durable immune responses in some patients. • In certain cases, patients have remained cancer-free for multiple years during follow-up. • The vaccines are